Microcap Ledger VivoSim Labs, INC. $VIVS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Diego, CA
- Fiscal year end
- March 31
- Shares outstanding
- 14,850,612 [10-Q 2026-08-12]
What the company doesAI summary of filing
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that provides testing of drugs and drug candidates using three-dimensional human tissue models of liver and intestine. The company offers liver and intestinal toxicology insights to pharmaceutical and biotech partners using its proprietary new approach methodologies (NAM) models, and expects to offer additional services in investigational toxicology and mechanism of drug action studies. In March 2025, the company sold its FXR314 drug development program to Eli Lilly for $10 million upfront plus potential milestone payments, and shifted its focus to the services business. The company is pre-revenue from its services platform and is currently in the stage of establishing commercial relationships with pharmaceutical partners while pursuing internal research and development activities. [10-K 2026-07-14]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 3 months to Jun 2026 | $18.0K | −$1.34M | −$3.21M | $1.67M | [10-Q 2026-08-12] |
| FY ended Mar 2026 | $131.0K | −$13.84M | −$10.83M | $5.02M | [10-K 2026-07-14] |
| FY ended Mar 2025 | $144.0K | −$2.49M | −$9.46M | $11.31M | [10-K 2026-07-14] |
- Quarterly cash burn
- −$3.21M
- Cash runway Estimate
- ~1.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 15,365,826 | [10-Q 2024-11-08] |
| 2025-02-01 | 17,454,473 | [10-Q 2025-02-19] |
| 2025-06-01 | 2,599,797 | [10-K/A 2025-07-29] |
| 2025-08-01 | 2,599,797 | [10-Q 2025-08-12] |
| 2025-11-01 | 2,607,962 | [10-Q 2025-11-06] |
| 2026-02-01 | 2,607,962 | [10-Q 2026-02-11] |
| 2026-07-10 | 3,494,071 | [10-K 2026-07-14] |
| 2026-08-10 | 14,850,612 | [10-Q 2026-08-12] |
- Shelf registration
- S-1 filed 2026-07-31; declared effective 2026-08-10 [S-1 2026-07-31]
Listing status
Current status: 4 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-21. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-08-21 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-21] |
| 2026-07-24 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-24] |
| 2025-02-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-25] |
| 2025-01-17 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-17] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-31 | Lialin Tony Serge | buy | 10,000 | $0.28 | [4 2026-09-01] |
| 2026-01-27 | Cohen Douglas Jay | grant | 15,000 | — | [4 2026-01-29] |
| 2026-01-27 | Murphy Keith | grant | 15,000 | — | [4 2026-01-29] |
| 2026-01-27 | Milhous Alison Tjosvold | grant | 15,000 | — | [4 2026-01-29] |
| 2026-01-27 | Gobel David | grant | 15,000 | — | [4 2026-01-29] |
| 2026-01-27 | Stern Adam K | grant | 15,000 | — | [4 2026-01-29] |
| 2025-11-17 | Gobel David | sell | 3,266 | $2.24 | [4 2025-11-19] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-06 | 8-K | Director or officer change; Shareholder vote results |
| 2026-08-21 | 8-K | Listing notice or transfer |
| 2026-08-21 | DEF 14A | Proxy statement |
| 2026-08-17 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-10 | PRE 14A | Proxy statement |
| 2026-08-06 | 8-K | Results of operations |
| 2026-07-31 | S-1 | Registration statement |
| 2026-07-30 | 8-K | Other events |
| 2026-07-24 | 8-K | Listing notice or transfer; Other events |
| 2026-07-17 | 8-K | Material agreement entered; Unregistered sale of equity; Other events |
| 2026-07-14 | 10-K | Annual report |
Alerts for $VIVS
Email me when VivoSim Labs, INC. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.